GlassScriptPhysician profile
Vijay Chaudhary
NPI 1134388051
$3,497.66
in general payments reported to CMS, 2019-2025
33 companies · $23.82 in 2025
The $23.82 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $592 · 2020: $124 · 2021: $2,061 · 2022: $203 · 2023: $351 · 2024: $143 · 2025: $23.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $517.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $2,063.00 | 2021-2023 | Bavencio |
| Pfizer INC. | $150.34 | 2019-2023 | |
| Sirtex Medical INC | $143.43 | 2024 | Sir-Spheres Microspheres |
| Novocure INC. | $119.35 | 2023 | |
| Abbott Laboratories | $113.39 | 2021-2022 | |
| Janssen Biotech, INC. | $112.18 | 2019-2023 | Erleada |
| Blue Earth Diagnostics | $97.93 | 2022 | |
| Novartis Pharmaceuticals Corporation | $74.37 | 2019-2023 | |
| Genentech USA, INC. | $63.71 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $54.28 | 2019-2020 | |
| Exelixis INC. | $52.21 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.00 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $40.74 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.17 | 2019 | |
| Celgene Corporation | $33.02 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $32.02 | 2019-2020 | |
| Daiichi Sankyo INC. | $30.03 | 2019-2022 | |
| Nuvation Bio INC. | $23.82 | 2025 | Ibtrozi |
| Taiho Oncology, INC. | $23.25 | 2019 | |
| Coherus Oncology, INC. | $20.04 | 2020 | |
| Tesaro, INC. | $19.35 | 2019 | |
| Alexion Pharmaceuticals, INC. | $16.49 | 2019 | |
| Array Biopharma INC | $16.43 | 2023 | Lorbrena, Mektovi, Braftovi |
| Abbvie INC. | $16.40 | 2019 | |
| Amgen INC. | $16.24 | 2019 | |
| Rigel Pharmaceuticals, INC. | $15.32 | 2019 | |
| Seagen INC. | $15.02 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $14.16 | 2020 | |
| Genzyme Corporation | $12.73 | 2019 | |
| Shire North American Group INC | $12.10 | 2019 | |
| Kyowa Kirin, INC. | $11.14 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vijay Chaudhary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.